Impact of GAD65 and IA2 autoantibodies on islet allograft survival.
GAD65 autoantibody
IA2 autoantibody
allograft survival
autoantibodies
islet transplantation
type 1 diabetes
Journal
Frontiers in clinical diabetes and healthcare
ISSN: 2673-6616
Titre abrégé: Front Clin Diabetes Healthc
Pays: Switzerland
ID NLM: 9918266295306676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
07
2023
accepted:
02
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Islet transplantation (ITx) shows promise in treating T1D, but the role of islet autoantibodies on graft survival has not been clearly elucidated. We aimed to analyze the effect of GAD65 and IA2 autoantibody status on graft survival and attainment of insulin independence in subjects with T1D who underwent ITx. We conducted a retrospective cohort study on 47 ITx recipients from 2000 to 2018. Islet infusion was performed via intrahepatic portal (n=44) or onto the omentum via laparoscopic approach (n=3). Immunosuppression involved anti-IL2 receptor antibody, anti-TNF, and dual combinations of sirolimus, tacrolimus, or mycophenolate mofetil (Edmonton-like) in 38 subjects (80.9%). T-cell depletion induction with Edmonton-like maintenance was used in 9 subjects (19%). GAD65 and IA2 autoantibodies were assessed pre-transplant and post-transplant (monthly) until graft failure, and categorized as persistently negative, persistently positive, or seroconverters. Graft survival was analyzed using U-Mann-Whitney test, and Quade's nonparametric ANCOVA adjusted for confounders. Kaplan-Meier and Log-Rank tests were employed to analyze attainment of insulin independence. P value <0.05 indicated statistical significance. ITx recipients with persistent autoantibody negativity (n = 21) showed longer graft function (98 [61 - 182] months) than those with persistent autoantibody positivity (n = 18; 38 [13 - 163] months), even after adjusting for immunosuppressive induction protocol (P = 0.027). Seroconverters (n=8) had a median graft survival time of 73 (7.7 - 167) months, which did not significantly differ from the other 2 groups. Subjects with persistently single antibody positivity to GAD65 (n = 8) had shorter graft survival compared to negative islet autoantibody (GAD65/IA2) subjects (n = 21; P = 0.016). Time of graft survival did not differ in subjects with single antibody positivity to IA2. The proportion of insulin independence attainment was similar irrespective of autoantibody status. The persistence of islet autoantibodies, as markers of islet autoimmunity, may represent an underappreciated contributing factor to the failure of transplanted β cells. Whether induction with T-cell depletion may lead to improved graft survival, independent of islet autoantibody status, could not be evaluated in our cohort. Larger prospective studies are needed to further address the role of islet autoantibody status on islet graft survival.
Identifiants
pubmed: 38028981
doi: 10.3389/fcdhc.2023.1269758
pmc: PMC10679328
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1269758Informations de copyright
Copyright © 2023 Lemos, Poggioli, Ambut, Bozkurt, Alvarez, Padilla, Vendrame, Ricordi, Baidal and Alejandro.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Transplantation. 2011 Sep 27;92(6):674-7
pubmed: 21792090
J Clin Med. 2021 Jun 19;10(12):
pubmed: 34205321
Diabetes Care. 2016 Jun;39(6):1060-4
pubmed: 27208324
Clin Exp Immunol. 2012 Aug;169(2):190-8
pubmed: 22774994
Am J Transplant. 2008 Jun;8(6):1262-74
pubmed: 18444924
Front Immunol. 2022 Apr 08;13:868343
pubmed: 35464438
N Engl J Med. 2000 Jul 27;343(4):230-8
pubmed: 10911004
Am J Transplant. 2004 Oct;4(10):1697-702
pubmed: 15367227
Immunity. 2010 Apr 23;32(4):468-78
pubmed: 20412757
Curr Diab Rep. 2013 Oct;13(5):704-12
pubmed: 23943207
Diabetes. 1997 Nov;46(11):1907-10
pubmed: 9356046
Front Immunol. 2021 Oct 21;12:772017
pubmed: 34745148
Diabetes. 2013 May;62(5):1656-64
pubmed: 23274902
Transplantation. 2013 Oct 27;96(8):745-52
pubmed: 23912172
Diabetes. 2009 Oct;58(10):2267-76
pubmed: 19602536
Transplantation. 2021 Nov 1;105(11):2490-2498
pubmed: 33481552
Curr Diab Rep. 2011 Dec;11(6):533-42
pubmed: 21912932
N Engl J Med. 2006 Sep 28;355(13):1318-30
pubmed: 17005949
Curr Opin Endocrinol Diabetes Obes. 2017 Aug;24(4):285-291
pubmed: 28509692
Diabetes Metab. 2000 May;26(3):215-8
pubmed: 10880896
Diabetes. 1999 Mar;48(3):652-7
pubmed: 10078573
Diabetes Care. 2009 Aug;32(8):1473-8
pubmed: 19638525
Diabetes Care. 2012 Jul;35(7):1436-45
pubmed: 22723582
Transplantation. 2008 Mar 27;85(6):801-12
pubmed: 18360260
Diabetes. 2003 May;52(5):1128-36
pubmed: 12716742
Lancet. 2016 Jun 4;387(10035):2331-2339
pubmed: 27302272
Am J Transplant. 2016 Jan;16(1):235-45
pubmed: 26317167
Diabetologia. 2012 Jul;55(7):1926-36
pubmed: 22441569
Am J Transplant. 2005 Aug;5(8):2037-46
pubmed: 15996257
Endocr Rev. 2021 Sep 28;42(5):584-604
pubmed: 33881515
Diabetes. 1999 Mar;48(3):484-90
pubmed: 10078547
Diabetes. 2010 Apr;59(4):947-57
pubmed: 20086230
Diabetes. 2001 Nov;50(11):2464-71
pubmed: 11679423